FORA Capital’s Royalty Pharma RPRX Stock Holding History

FORA Capital’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-41,084	Closed	-$1.73M	–	540
2022 Q2	$1.73M	Buy	41,084 +30,623	+293%	+$1.26M	0.34%	88
2022 Q1	$408K	Buy	+10,461	New	+$411K	0.07%	322
2021 Q3	–	Sell	-14,877	Closed	-$610K	–	770
2021 Q2	$610K	Buy	+14,877	New	+$633K	0.11%	218
2021 Q1	–	Sell	-42,348	Closed	-$2.12M	–	1048
2020 Q4	$2.12M	Buy	+42,348	New	+$1.8M	0.32%	64

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SGA

Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

FORA Capital's RPRX Position: Q3 2022 in Review

FORA Capital sold out of Royalty Pharma (RPRX) in Q3 2022, closing a stake of 41,084 shares — an estimated $1.73M sold.

FORA Capital first reported a position in RPRX in Q4 2020 and held it in 4 quarters. The position peaked at $2.12M in Q4 2020. 319 funds tracked by Wall St. Rank hold RPRX as of Q3 2022.

FORA Capital reported no remaining Royalty Pharma position as of Q3 2022 after selling out during the quarter.
FORA Capital sold 41,084 Royalty Pharma shares in Q3 2022, an estimated $1.73M.
FORA Capital first reported a position in Royalty Pharma in Q4 2020 and held it in 4 quarters.
FORA Capital's Royalty Pharma position peaked at $2.12M in Q4 2020.
319 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2022.

Based on FORA Capital's 13F filing for Q3 2022, filed 14 Nov 2022.